Expanded Access to Triheptanoin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03773770|
Expanded Access Status : Available
First Posted : December 12, 2018
Last Update Posted : February 13, 2020
|Condition or disease||Intervention/treatment|
|Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)||Drug: Triheptanoin|
LC-FAOD Conditions: Available through Intermediate-Size Population Expanded Access.
The intermediate-size expanded access treatment protocol is intended to provide rapid access to triheptanoin for the treatment of seriously ill patients with long-chain fatty acid oxidation disorders (LC-FAOD).
Patients will be treated under this protocol for the duration of one year, with consideration on a yearly basis for extension of treatment based on the risk-benefit ratio assessed in the Treating Physician's quarterly progress reports. Patients may continue to receive triheptanoin under this intermediate-size treatment protocol until commercial availability of triheptanoin, should the drug receive regulatory approval.
Non-FAOD Conditions: Available through Single Patient Expanded Access. Expanded access may provide access for treatment prior to approval by the local regulatory agency.
For full details, please visit the link provided.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients, Intermediate-size Population|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||UX007-EAP101: An Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patients With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) With Triheptanoin (UX007)|
- Drug: Triheptanoin
Liquid for oral (PO) or enteral tube administrationOther Name: UX007
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03773770
|Contact: Early Access||1-415-483-8800||EarlyAccess@ultragenyx.com|
|Study Director:||Medical Director||Ultragenyx Pharmaceutical Inc|